|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Customer revenue | |||||
| Collaboration revenue | |||||
| Total revenue | |||||
| Operating expenses | |||||
| Research and development | |||||
| General and administrative | |||||
| Asset impairment | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Other (expense) income: | |||||
| Interest income | |||||
| Grant income | |||||
| Interest expense - royalty agreement | |||||
| Interest expense - convertible notes payable | |||||
| Fair value adjustments on derivative liabilities - royalty agreement | |||||
| Fair value adjustments on convertible notes payable | |||||
| Fair value adjustments on derivative liabilities - contingent value right liability | |||||
| Gain on extinguishment - royalty agreement | |||||
| Other income - German R&D tax credit receivable | |||||
| Interest income, net | |||||
| Other income (expense), net | |||||
| Loss before income taxes | |||||
| Income tax benefit (expense) | |||||
| Net loss | |||||
| Less: Cumulative Series D preferred dividends | |||||
| Net (loss) income attributable to common stockholders | |||||
| Other comprehensive loss: | |||||
| Foreign currency translation gain | |||||
| Unrealized gain (loss) on available-for-sale securities | |||||
| Comprehensive loss | |||||
| Net loss per share of Common Stock - basic (in dollars per share) | |||||
| Net loss per share of Common Stock - diluted (in dollars per share) | |||||
| Weighted-average shares used in computing net loss per share of Common Stock - basic (in shares) | |||||
| Weighted-average shares used in computing net loss per share of Common Stock - diluted (in shares) |
Loading...